Drugs & Aging

, Volume 30, Issue 7, pp 513–525 | Cite as

Risk versus Benefit of Non-Vitamin K Dependent Anticoagulants Compared to Warfarin for the Management of Atrial Fibrillation in the Elderly

Review Article


The objective of this review was to compare the safety and efficacy of dabigatran, rivaroxaban and apixaban to warfarin for the management of atrial fibrillation (AF) in older adults. The prevalence and incidence of AF increase with age. Approximately 5 % of the United States population over the age of sixty-five years and 10 % over the age of seventy-nine years have AF. AF is associated with increased risk for thromboembolic events. Despite the increasing incidence and prevalence of AF in older adults and the risks of thromboembolic events, clinicians often avoid anticoagulants. Specifically with warfarin, the risk of hemorrhage may outweigh the benefit in stroke risk reduction in certain populations. Aspirin, while safer to use, is not as effective as warfarin in stroke risk reduction. Newer non-vitamin K dependent antithrombotic therapies (e.g. dabigatran, rivaroxaban, and apixaban) are redefining thromboprophylaxis of AF. Dabigatran, rivaroxaban, and apixaban are at least as effective as warfarin in stroke risk reduction. With new mechanisms of action and no need for therapeutic drug monitoring, countless new patients are potential candidates for anticoagulation. However patient adherence, lack of a reversal agent, cost, and other safety concerns remain reasons for caution and careful consideration. Furthermore, older adults exhibited greater adverse effects from these agents across the clinical trials. This review will examine the newer anticoagulants safety and efficacy with particular attention to their role in treating older adults with AF. Alternatives to warfarin therapy now exist for thromboprophylaxis of AF. Whether these agents represent advances in overall safety in older adults remains uncertain. More experience and research are needed before endorsing their widespread use as a replacement for warfarin in the geriatric population.


Conflict of interest statement

The authors of this manuscript report no conflict of interest related to this subject matter.


  1. 1.
    Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2006;48:854–906.PubMedCrossRefGoogle Scholar
  2. 2.
    Heeringa J, Van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam Study. Eur Heart J. 2006;27:949–53.PubMedCrossRefGoogle Scholar
  3. 3.
    Marinigh R, Lip G, Fiotti N, Giansante C, Lane D. Age as a risk factor for stroke in atrial fibrillation patients. J Am Coll Cardiol. 2010;56:827–37.PubMedCrossRefGoogle Scholar
  4. 4.
    Ezekowitz M, Bridgers S, James K, et al. VA co-operative study of warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Rockson SG, Albers GW. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. Am Coll Cardiol. 2004;43(6):929–35.CrossRefGoogle Scholar
  6. 6.
    Lip GYH, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010;123(6):484–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Guyatt GH, Akl E, Crowther M, et al. Executive summary: antithrombotic therapy and prevention of thrombus, 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):7S–47S.PubMedCrossRefGoogle Scholar
  8. 8.
    The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505–11.CrossRefGoogle Scholar
  9. 9.
    The Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527–39.CrossRefGoogle Scholar
  10. 10.
    Connolly S, Laupacis A, Gent M. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18:349–55.PubMedCrossRefGoogle Scholar
  11. 11.
    Petersen P, Godtfredsen J, Boysen G, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complication in chronic atrial fibrillation: The Copenhagen AFSAK study. Lancet. 1989;1:175–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–57.CrossRefGoogle Scholar
  13. 13.
    Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118(20):2029–37.PubMedCrossRefGoogle Scholar
  14. 14.
    McCrory D, Matchar D, Samsa G, et al. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995;155(3):277–81.PubMedCrossRefGoogle Scholar
  15. 15.
    Phillips KW, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Expert Rev Cardiovasc Ther. 2008;6(1):57–70.PubMedCrossRefGoogle Scholar
  16. 16.
    Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol. 2001;38:1231–66.PubMedCrossRefGoogle Scholar
  17. 17.
    McCormick D, Gurwitz J, Goldberg R, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001;161(20):2458–63.PubMedCrossRefGoogle Scholar
  18. 18.
    Aspinall SL, Zhao X, Handler SM, et al. The quality of warfarin prescribing and monitoring in Veteran Affairs Nursing homes. J Am Geriatr Soc. 2010;58(8):1475–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Young S, Bishop L, Twells L, et al. Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. BMC Fam Pract. 2011;12:88.PubMedCrossRefGoogle Scholar
  20. 20.
    Mangoni A, Jackson S. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.PubMedCrossRefGoogle Scholar
  21. 21.
    Brunton L, Chabner B, Knollmann B. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 12th ed. New York: The McGraw-Hill Companies, Inc.; 2011.Google Scholar
  22. 22.
    Fang M, Chang Y, Hylek E, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141:745–52.PubMedCrossRefGoogle Scholar
  23. 23.
    Levine M, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest. 1989;95:26S–36S.PubMedGoogle Scholar
  24. 24.
    Forfar J. A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment. Br Heart J. 1979;42:128–32.PubMedCrossRefGoogle Scholar
  25. 25.
    Fihn S, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med. 1993;118:511–20.PubMedCrossRefGoogle Scholar
  26. 26.
    Palareti G, Hirsh J, Legnani C, et al. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med. 2000;160(4):470–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689–96.PubMedCrossRefGoogle Scholar
  29. 29.
    Albers G. Three new studies, three remaining questions. Arch Intern Med. 1994;154:1443–57.PubMedCrossRefGoogle Scholar
  30. 30.
    Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in Atrial Fibrillation II Study. Lancet. 1994;343:687–91.Google Scholar
  31. 31.
    White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167:239–45.PubMedCrossRefGoogle Scholar
  32. 32.
    Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503.PubMedCrossRefGoogle Scholar
  33. 33.
    Poli D, Antonucci E, Grifoni E, et al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol. 2009;54(11):999–1002.PubMedCrossRefGoogle Scholar
  34. 34.
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.PubMedCrossRefGoogle Scholar
  35. 35.
    Patel M, Mahaffey K, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.PubMedCrossRefGoogle Scholar
  36. 36.
    Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.PubMedCrossRefGoogle Scholar
  37. 37.
    Beasley BN, Unger EF, Temple R. Anticoagulant options—why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364(19):1788–90.PubMedCrossRefGoogle Scholar
  38. 38.
    Hunchuck JE, Lake JD. Dabigatran for stroke prevention in all patients with atrial fibrillation? Pharmacotherapy. 2011;31(8):725–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–72.PubMedCrossRefGoogle Scholar
  40. 40.
    Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397–402.PubMedCrossRefGoogle Scholar
  41. 41.
    Quarter Watch. Dabigatran(Pradaxa) and serious bleeding in the elderly. Institute for Safe Medication Practices. 2012. http://www.ismp.org/QuarterWatch/pdfs/2011Q1.pdf. Accessed 20 Apr 2012.
  42. 42.
    Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765–75.PubMedCrossRefGoogle Scholar
  43. 43.
    Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776–86.PubMedCrossRefGoogle Scholar
  44. 44.
    Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled study. Lancet. 2008;372(9632):31–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873–80.PubMedCrossRefGoogle Scholar
  46. 46.
    Kubitza D, Becka M, Roth A, et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008;24(10):2757–65.PubMedCrossRefGoogle Scholar
  47. 47.
    Clinical Trials.gov. Evaluation of the efficacy and safety of rivaroxaban (BAY59-7939) for the prevention of stroke and non-central nervous system systemic embolism in subjects with non-valvular atrial fibrillation. http://clinicaltrials.gov/ct2/show/NCT00494871. Accessed 15 Apr 2012.
  48. 48.
    Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877–85.PubMedCrossRefGoogle Scholar
  49. 49.
    Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594–604.PubMedCrossRefGoogle Scholar
  50. 50.
    Buller H, Deitchman D, Prins M, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis: the Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6(8):1313–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17.PubMedCrossRefGoogle Scholar
  52. 52.
    Australian Public Assessment Report for Apixaban. Therapeutic Goods Administration. Woden ACT 2606 Australia. http://www.tga.gov.au/pdf/auspar/auspar-eliquis.pdf. Accessed 17 Apr 2012.
  53. 53.
    Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost. 2012;108(3):476–84. doi:10.1160/TH12-02-0093.PubMedCrossRefGoogle Scholar
  54. 54.
    Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs. warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ. 2012;15(4):776–85.PubMedCrossRefGoogle Scholar
  55. 55.
    Alia A, Bailey C, Abdelhafiz A. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis. Age Ageing. 2012;41(5):681–4.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Virginia Commonwealth UniversityRichmondUSA
  2. 2.University of Connecticut School of PharmacyStorrsUSA
  3. 3.Yale University School of MedicineNew HavenUSA
  4. 4.VA Connecticut Healthcare SystemWest HavenUSA

Personalised recommendations